Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studyFunda Meric‐Bernstam, John D. Hainsworth, Howard A. Burris et al.|The Lancet Oncology|2019Cited by 564
Risk-Reducing Salpingo-Oophorectomy in <i>BRCA</i> Mutation Carriers: Role of Serial Sectioning in the Detection of Occult MalignancyC. Bethan Powell, John L. Ziegler, Eric Kenley et al.|Journal of Clinical Oncology|2004Cited by 375
Recruitment, Genetic Counseling, and <i>BRCA</i> Testing for Underserved Women at a Public HospitalRobin Lee, John L. Ziegler, Mary Beattie et al.|Genetic Testing|2005Cited by 39
Development and Pilot Evaluation of Novel Genetic Educational Materials Designed for an Underserved Patient PopulationRebecca Lubitz, John L. Ziegler, Miriam Komaromy et al.|Genetic Testing|2007Cited by 29